A 48-week, Multi-center, Randomized, Open Label, Parallel Group Comparison of the Comprehensive Glycemic Control of Saxagliptin and Glimepiride in Patients Inadequately Controlled With Metformin Monotherapy patients With Type 2 Diabetes

Trial Profile

A 48-week, Multi-center, Randomized, Open Label, Parallel Group Comparison of the Comprehensive Glycemic Control of Saxagliptin and Glimepiride in Patients Inadequately Controlled With Metformin Monotherapy patients With Type 2 Diabetes

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Glimepiride (Primary) ; Saxagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2016 Results (n=64) assessing the role of alpha and beta-cell functions, blood glucagon level in predicting the efficacy of saxagliptin, published in the Diabetes Therapy journal.
    • 31 Oct 2016 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top